| 1) Patients with both classical MP-positive a |
| 2) Patients with filigree-predominant ADC sho |
| 3) Patients with malignancy and solid-organ t |
| 4) Patients with pretreatment ApoC-II levels |
| 5) Patients with severe visual vertigo improv |
| 6) ollected primary care records to identify patients with 'high-risk' conditions, incl |
| 7) They are disrupted in patients with 22q11.2 deletion syndrome, d |
| 8) is of single nuclei from brain tissues of patients with AD carrying the R47H mutatio |
| 9) Therefore, subtyping patients with AD is a critical step toward |
| 10) -Hispanic white individuals including 109 patients with AD, 356 mild cognitive impai |
| 11) icrometastasis indicated poor survival in patients with ADC with the filigree patter |
| 12) Intrarenal scRNA-Seq transcriptomes in patients with AKI-defined cell populations |
| 13) c EEG abnormalities are present in 80-90% patients with AS. |
| 14) and rituximab (FCR) in untreated younger patients with CLL. |
| 15) l GCMH-related pathologies in smokers and patients with COPD. |
| 16) that although approximately two-thirds of patients with COVID-19 had symptoms of kid |
| 17) s in acutely meeting the medical needs of patients with COVID-19 while continuing es |
| 18) ctive smokers were underrepresented among patients with COVID-19, claimed that a "sm |
| 19) atinine was reported for up to 60% of the patients with COVID-19, the overall preval |
| 20) nd clinical outcomes among critically ill patients with COVID-19. |
| 21) is was performed of 693 Japanese COVID-19 patients with CVDRF enrolled in the nation |
| 22) Conclusions: One-third of COVID patients with CVDRF required ICU care duri |
| 23) A cohort of 57 head-and-neck cancer patients with DECT and MRI pairs were used |
| 24) The results revealed that patients with HGSOC and the TT genotype at |
| 25) In summary, patients with HGSOC and the TT genotype at |
| 26) at the rs6983267 locus (GG, GT, TT) in 98 patients with HGSOC. |
| 27) associated with CKD but was restricted in patients with HIV viremia, regardless of C |
| 28) onal consequence of six VUS identified in patients with IRD. |
| 29) e presentation and clinical management of patients with IgAn in Europe and Japan. |
| 30) es of these molecules in the NALT/BALT of patients with IgAn. |
| 31) addition to the serious somatic symptoms, patients with MD also experience problems |
| 32) itive functioning and/or mental health in patients with MD and their relatives. |
| 33) itive impairments and mental disorders in patients with MD. |
| |